Cargando…

A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck

This study was designed to evaluate the activity, safety and tolerance of docetaxel (D) in a selected population with metastatic squamous cell carcinoma of the head and neck (SCCHN). Twenty-four patients with no prior palliative therapy were enrolled and received D 100 mg m(−2) by 1 h of infusion, e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Couteau, C, Chouaki, N, Leyvraz, S, Oulid-Aissa, D, Lebecq, A, Domenge, C, Groult, V, Bordessoule, S, Janot, F, Forni, M De, Armand, J-P
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362927/ https://www.ncbi.nlm.nih.gov/pubmed/10507770 http://dx.doi.org/10.1038/sj.bjc.6690715

Ejemplares similares

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck
por: Pivot, X, et al.
Publicado: (2001)

Docetaxel in the treatment of squamous cell carcinoma of the head and neck
por: Rapidis, Alexander, et al.
Publicado: (2008)

Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
por: Kim, Moon Jin, et al.
Publicado: (2019)

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck
por: Posner, M R, et al.
Publicado: (2003)

Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas
por: Wijffels, K I E M, et al.
Publicado: (2000)

The role of genetic factors in predisposition to squamous cell cancer of the head and neck
por: Jefferies, S, et al.
Publicado: (1999)

Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Kafri, Zyad, et al.
Publicado: (2012)

Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas
por: William, William N., et al.
Publicado: (2018)

Differential expression of a novel serine protease homologue in squamous cell carcinoma of the head and neck
por: Lang, J C, et al.
Publicado: (2001)

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
por: Trieu, Vanessa, et al.
Publicado: (2018)

p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy
por: Ganly, I, et al.
Publicado: (2000)

Metabolism and growth inhibition of four retinoids in head and neck squamous normal and malignant cells
por: Klaassen, I, et al.
Publicado: (2001)

Proton therapy for non-squamous cell carcinoma of the head and neck: planning comparison and toxicity
por: Iwata, Hiromitsu, et al.
Publicado: (2019)

PD 098059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma
por: Simon, C, et al.
Publicado: (1999)

Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas
por: Mineta, H, et al.
Publicado: (2000)

Osteopontin Levels in Patients with Squamous Metastatic Head and Neck Cancer
por: Maleš, Josip, et al.
Publicado: (2021)

Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Hsieh, Ronan W., et al.
Publicado: (2021)

Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study
por: Okada, S, et al.
Publicado: (1999)

Effect of photodynamic therapy in combination with ionizing radiation on human squamous cell carcinoma cell lines of the head and neck
por: Allman, R, et al.
Publicado: (2000)

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Borel, Christian, et al.
Publicado: (2020)

Prognostic value of the expression of epithelial cell adhesion molecules in head and neck squamous cell carcinoma treated by definitive radiotherapy
por: Murakami, Naoya, et al.
Publicado: (2019)

Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck
por: Schell, Amy, et al.
Publicado: (2015)

Response Rate of Cisplatin Plus Docetaxel as Primary Treatment in Locally Advanced Head and Neck Carcinoma (Squamous Cell Types)
por: Nouman, Maryum, et al.
Publicado: (2020)

Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma
por: Chou, Ming-Huei, et al.
Publicado: (2021)

No germline mutations in CDKN2A (p16) in patients with squamous cell cancer of the head and neck and second primary tumours
por: Jefferies, S, et al.
Publicado: (2001)

Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer
por: Posch, Doris, et al.
Publicado: (2016)

First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study
por: Falco, Agustín, et al.
Publicado: (2022)

Metabolomic analysis identifies differentially produced oral metabolites, including the oncometabolite 2-hydroxyglutarate, in patients with head and neck squamous cell carcinoma
por: Mukherjee, Pranab K., et al.
Publicado: (2016)

High prevalence of p16 genetic alterations in head and neck tumours
por: Miracca, E C, et al.
Publicado: (1999)

Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands
por: van der Linden, Naomi, et al.
Publicado: (2015)

Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population
por: Chen, Wen-Chun, et al.
Publicado: (2017)

Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer
por: Fuchs, Hannah, et al.
Publicado: (2018)

Performance and standards for the process of head and neck cancer care: South and West audit of head and neck cancer 1996–1997 (SWAHN I)
por: Birchall, M A, et al.
Publicado: (2000)

Aberrant expression of cyclin A in head and neck cancer
por: Lotayef, M, et al.
Publicado: (2000)

Development of a prediction model for head and neck volume reduction by clinical factors, dose–volume histogram parameters and radiomics in head and neck cancer
por: Ishizawa, Miyu, et al.
Publicado: (2023)

The role of miR-21 as a predictive biomarker and a potential target to improve the effects of chemoradiotherapy against head and neck squamous cell carcinoma
por: Ishinaga, Hajime, et al.
Publicado: (2023)

Telomerase activation cooperates with inactivation of p16 in early head and neck tumorigenesis
por: Soria, J C, et al.
Publicado: (2001)

The effect of docetaxel on retinal pigment epithelial cells
por: Li, Jialin, et al.
Publicado: (2022)

Efficacy and safety of nanosomal docetaxel lipid suspension-based chemotherapy in squamous cell carcinoma of the head and neck: A multicenter retrospective study
por: Kumar Das Majumdar, Saroj, et al.
Publicado: (2020)

Circulating tumor cell analysis in locally advanced and metastatic squamous cell carcinoma of the head and neck
por: Harris, Ethan J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i1goscbhfvreb2l4out253qp49